New US dedicated trainer account

RNS Number : 9253K

Deltex Medical Group PLC

22 April 2015

 



22 April 2015

Deltex Medical Group plc

("Deltex Medical", "the Company" or "the Group")

New US dedicated trainer account

Deltex Medical Group plc (LSE-AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), today announces that it has established its ninth dedicated trainer account in the USA.

The new account is a highly prestigious teaching hospital in Boston, Massachusetts and is part of a healthcare system that includes six major hospitals. The decision to move forward with ODM follows a successful clinical evaluation of CardioQ-ODM+ completed in September 2014 as part of a quality improvement initiative. This initiative was focused around an evidence based enhanced recovery approach to surgery. Procurement of at least 500 probes has now been formally approved for inclusion in the hospital's 2015/16 budget year starting in October 2015. In the interim the hospital is purchasing probes on an ad hoc basis and has placed three orders of 50 probes each time over the last four months.

This is the first new dedicated trainer account to be established in the North-East region of the USA since the sales territory was created in the first quarter of 2015.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"This is the third new dedicated trainer account established this year and the ninth in total. It is another key step towards our strategy of building, by mid-2016, a strong platform for future national roll-out of ODM in the key US market."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Barry Curtis, Company Secretary
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson	020 7533 7727
Financial Public Relations
Newgate	020 7653 9850
Tim Thompson
Robyn McConnachie Ed Treadwell

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

END

 

 

NRAIBMMTMBATTIA